Each of the component projects of this program project application involves the theoretical design of dosing regimens that would result in a particular drug exposure. The experimental implementation of those dosing regimens and the validation that experimentally achieved exposures approximate those that were intended are an integral part of each project. This overarching strategy applies to both the in vitro hollow fiber studies and in vivo animal studies proposed in the component studies. Validation of experimentally acheived exposures is accomplished by sampling over the course of the experiment for the purpose of measuring drug concentrations at appropriate time points. The timely, accurate and cost-efficient assay of the antibiotic and antiviral agents to be used in these studies in sample matrices such as complex growth media and animal serum and tissues lies outside the experience of most biomedical scientists. The presence of an in-house analytical core facility that can meet those objectives, serve as a resource in the planning of studies and maintain a collegial relationship with the investigators is crucial to the success of the proposed studies. It is therefore proposed that an analytical core support the investigators participating in this program project. The sevices provided by the analytical core include the development and validation of assays for each drug used in these projects, providing assistance to the investigators in designing preliminary experiments that verify the fidelity with which the hollow fiber system simulates the agent's pharmacokinetics and providing advice regarding the fabrication and setup of hollow fiber systems, particularly if modifications are required to optimize the application of the systems to a particular study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060908-05
Application #
7901023
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
2011-08-15
Budget Start
2009-07-01
Budget End
2011-08-15
Support Year
5
Fiscal Year
2009
Total Cost
$266,013
Indirect Cost
Name
Ordway Research Institute, Inc.
Department
Type
DUNS #
124361945
City
Albany
State
NY
Country
United States
Zip Code
12208
Heine, Henry S; Louie, Arnold; Adamovicz, Jeffrey J et al. (2014) Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrob Agents Chemother 58:3276-84
Roberts, Jason A; Abdul-Aziz, Mohd H; Lipman, Jeffrey et al. (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498-509
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2013) Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Antimicrob Agents Chemother 57:5946-60
Louie, Arnold; VanScoy, Brian D; Brown, David L et al. (2012) Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother 56:1229-39
Louie, Arnold; Vanscoy, Brian D; Heine 3rd, Henry S et al. (2012) Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 56:513-7
Louie, A; Heine, H S; VanScoy, B et al. (2011) Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother 55:822-30
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2011) Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 55:2623-8
Bulitta, Jurgen B; Landersdorfer, Cornelia B; Forrest, Alan et al. (2011) Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-61
Drusano, G L; Okusanya, O O; Okusanya, A O et al. (2009) Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob Agents Chemother 53:4718-25
Louie, A; Heine, H S; Kim, K et al. (2008) Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 52:2486-96

Showing the most recent 10 out of 15 publications